Economic impact of potential drug-drug interactions in opioid analgesics

Journal of Medical Economics

Volumn 14, Issue 4, 2011, Pages 390-396

  Summers, Kent H ^a   Amy Puenpatom, R ^a   Rajan, Niveda ^a   Ben Joseph, Rami ^a   Ohsfeldt, Robert ^b  

^a Endo Pharmaceuticals   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Drug interactions; Economics econometrics; Opioid analgesics; Pharmacoeconomics

Indexed keywords

CYTOCHROME P450; OPIATE;

ARTICLE; CHRONIC PAIN; COMPARATIVE STUDY; DRUG EXPOSURE; DRUG INTERACTION; DRUG METABOLISM; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INSURANCE; PRESCRIPTION;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ECONOMICS, PHARMACEUTICAL; FEMALE; HEALTH SERVICES; HUMANS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PAIN; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79960112089     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2011.583302     Document Type: Article

References (36)

1. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30
2. Altman R. Practical considerations for the pharmacologic management of osteoarthris. Am J Manag Care 2009;15:S236-S243
3. Nicholas MK, Molloy AR, Brooker C. Using opioids with persisting noncancer pain: a biopsychosocial perspective. Clin J Pain 2006;22:137-46 (Pubitemid 44366963)
4. Hartshorn EA, Tatro DS. Principles of drug interactions. In: Tatro DS, ed. Drug Interaction Facts, 5th edn. St. Louis: Facts and Comparisons, 1996
5. Holmquist G. Opioid metabolism and effects of cytochrome P450. Pain Med 2009;10:S20-9
6. Prescribing Information, OxyContin-(oxycodone hydrochloride controlledrelease) Tablets Purdue Pharma L.P. Stamford, CT 301734-0C May 10, 2010
7. Kummer O, Hammann R, Moser C, et al. Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Eur J Clin Pharmacol 2010. [Epub ahead of print]
8. Nieminen TH, Hagelberg NM, Saari TI, et al. Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. Eur J Clin Pharmacol 2010;66:977-85
9. Chien JY, Mohutsky MA, Wrighton SA. Physiological approaches to the prediction of drug-drug interactions in study populations. Curr Drug Metab 2003;4:347-56 (Pubitemid 37279360)
10. Shou M LY, Lu P, Tang C, et al. Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab 2000;2:17-36
11. Reducing and preventing adverse drug events to decrease hospital costs. Research in Action, Issue 1. AHRQ, Agency for Healthcare Research and Quality http://www.ahrq.gov/qual/aderia/aderia.htm.2001. Accessed July 26, 2010
12. Bates D, Spell N, Cullen D, et al. The costs of adverse drug events in hospitalized patients. JAMA 1997;277:307-11 (Pubitemid 27045011)
13. Classen D, Pestotnik S, Eans R, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997;227:301-6 (Pubitemid 27045010)
14. Saurat J-H, Guerin A, Yu A, et al. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. Dermatology 2010;220:128-37
15. Cruciol-Souza JM, Thomson JC. A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clinics (Sao Paulo) 2006; 61:515-20
16. Becker ML, Hofman A, Stricker BHC. Increasing exposure to drug-drug interactions between 1992 and 2005 in people aged 455 years. Drugs Aging 2008;25:145-52 (Pubitemid 351225818)
17. Pergolizzi J, Labhsetwar S, Puenpatom R, et al. Exposure to potential CYP450 prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. Pain Pract 2010. [Epub ahead of print]
18. Pergolizzi J, Labhsetwar S, Puenpatom R, et al. Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions. Pain Pract 2010 doi: 10.1111/j, 1533-2500
19. Haijar E, Hanlon J, Artz M, et al. Adverse drug reaction risk factors in older outpatients. Am J Geriatr Pharmacother 2003;1:82-9 (Pubitemid 40410978)
20. McCaffery M, Pasero M. Pain: Clinical Manual. Philadelphia: Mosby, 1999
21. Slone Epidemiology Center. Patterns of Medication Use in the United States http://www.bu.edu/slone/SloneSurvey/AnnualRpt/SloneSurvey WebReport2006.pdf. Accessed October 5, 2010
22. Nguyen J, Fouts M, Kotabe S, et al. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother 2006;4:36-41
23. Gurwitz J, Field T, Harrold L, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289:1107-16 (Pubitemid 37430324)
24. Lötsch J Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 2005;29(5 Suppl):S90-103 (Pubitemid 40720250)
25. Kurz A, Sessler D. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs Aging 2003;63:649-71 (Pubitemid 36408072)
26. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 2001;182(5A Suppl):11-18S (Pubitemid 34072942)
27. Cadet P. Mu opiate receptor subtypes. Med Sci Monit 2004;10:MS28-32 (Pubitemid 38878790)
28. Hale M, Ahdieh H, Ma T, et al. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebocontrolled study. J Pain Symptom Manage 2007;8:175-84 (Pubitemid 46186162)
29. Robins J, Mark S, Newey W. Estimating exposure effects by modeling the expectation of exposure conditional on confounders. Biometrics 1992; 48:479-95
30. Rosenbaum P, Rubin D. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79:516-24
31. Barnett V, Lewis T. Outliers in Statistical Data, 3rd edn. Chichester, UK: Wiley, 1994
32. SAS 9 on Microsoft Windows, 2008, SAS Institute Inc., Cary, NC, USA
33. Armstrong S, Cozza K. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics 2003;44:167-71 (Pubitemid 36241127)
34. Solberg L, Hurley J, Roberts M, et al. Measuring patient safety in ambulatory care: potential for identifying group drug-drug interaction rates using claims data. Am J Manag Care 2005;10:753-9 (Pubitemid 39518521)
35. Dickson M, Bramley T, Kozma C, et al. Potential drug-drug interactions with antiepileptic drugs in Medicaid recipients. Am J Health-System Pharm 2008; 65:1983-91
36. Qato D, Alexander G, Conti R, et al. Use of prescription and over-the-counter medications and dietatry supplements among older adults in the United States. JAMA 2008;300:2867-78